Literature DB >> 31556408

Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib.

Fabiana Letizia Cecere1, Andres Aguilar2, Rafael Rosell2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31556408      PMCID： PMC6749130          DOI： 10.21037/tlcr.2019.08.20

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  11 in total

1.  A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.

Authors:  Meijuan Huang; Youling Gong; Jiang Zhu; Yi Qin; Feng Peng; Li Ren; Zhenyu Ding; Yongmei Liu; Chengzhi Cai; Yongsheng Wang; You Lu
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

2.  Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.

Authors:  Yan-Jun Mi; Yong-Ju Liang; Hong-Bing Huang; Hong-Yun Zhao; Chung-Pu Wu; Fang Wang; Li-Yang Tao; Chuan-Zhao Zhang; Chun-Ling Dai; Amit K Tiwari; Xiao-Xu Ma; Kenneth Kin Wah To; Suresh V Ambudkar; Zhe-Sheng Chen; Li-Wu Fu
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment.

Authors:  Kentaro Masuhiro; Takayuki Shiroyama; Izumi Nagatomo; Atsushi Kumanogoh
Journal:  J Thorac Oncol       Date:  2019-05       Impact factor: 15.609

4.  Unexpected role of natural killer cell-derived interferon-γ as a driver of NETosis and DVT.

Authors:  Christoph Becker; Christian Reinhardt
Journal:  J Thromb Haemost       Date:  2019-02       Impact factor: 5.824

Review 5.  Interleukin-33 in the developing lung-Roles in asthma and infection.

Authors:  Kristina Johansson; Henry J McSorley
Journal:  Pediatr Allergy Immunol       Date:  2019-03-18       Impact factor: 6.377

Review 6.  Cavitary Lung Diseases: A Clinical-Radiologic Algorithmic Approach.

Authors:  Khalid Gafoor; Shalin Patel; Francis Girvin; Nishant Gupta; David Naidich; Stephen Machnicki; Kevin K Brown; Atul Mehta; Bryan Husta; Jay H Ryu; George A Sarosi; Tomás Franquet; Johny Verschakelen; Takeshi Johkoh; William Travis; Suhail Raoof
Journal:  Chest       Date:  2018-03-06       Impact factor: 9.410

7.  Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.

Authors:  Jian-Chun Duan; Zhi-Jie Wang; Lin Lin; Jun-Ling Li; Yan Wang; Hua Bai; Xing-Sheng Hu; Yu-Tao Liu; Xue-Zhi Hao; Hong-Yu Wang; Rui Wan; Xin Wang; Jie Wang
Journal:  Invest New Drugs       Date:  2019-02-01       Impact factor: 3.850

8.  Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.

Authors:  Edith M Marom; Carlos H Martinez; Mylene T Truong; Xiudong Lei; Bradley S Sabloff; Reginald F Munden; Gregory W Gladish; Roy S Herbst; Rodolfo C Morice; David J Stewart; Carlos A Jimenez; George R Blumenschein; Amir Onn
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

9.  Neratinib augments the lethality of [regorafenib + sildenafil].

Authors:  Laurence Booth; Jane L Roberts; Rumeesa Rais; Richard E Cutler; Irmina Diala; Alshad S Lalani; John F Hancock; Andrew Poklepovic; Paul Dent
Journal:  J Cell Physiol       Date:  2018-09-10       Impact factor: 6.384

10.  Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.

Authors:  Chen Lin; Shanshan Wang; Weiwei Xie; Rongliang Zheng; Yu Gan; Jianhua Chang
Journal:  Oncotarget       Date:  2016-09-13
View more
  1 in total

1.  Cavity development: a potential biomarker for antiangiogenesis agents.

Authors:  Man Jiang; Xiaochun Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.